Close

Atossa Genetics (ATOS) Announces Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer

July 13, 2018 8:05 AM EDT Send to a Friend
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has opened a Phase 2 study of its proprietary oral Endoxifen ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login